STAT3 and MAPK in human lung cancer tissues and suppression of oncogenic growth by JAB and dominant negative STAT3

被引:5
|
作者
Seki, Y
Suzuki, N
Imaizumi, M
Iwamoto, T
Usami, N
Ueda, Y
Hamaguchi, M
机构
[1] Nagoya Univ, Grad Sch Med, Div Canc Biol, Showa Ku, Nagoya, Aichi 4668550, Japan
[2] Nagoya Univ, Grad Sch Med, Dept Thorac Surg, Showa Ku, Nagoya, Aichi 4668550, Japan
关键词
signal transduction; MAPK; STAT3; JAB; human lung cancer; carcinogenesis;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To search for the signaling events in lung carcinoma relevant to its tumorigenesis, we investigated the phosphorylation of MAPK and STAT3 in human lung carcinoma tissues and their paired normal tissues. Although relative amounts of MAPK levels differed among the cases examined, no clear difference in MAPK levels was observed between tumor tissues and their paired normal tissues. Of 79 cases examined, only 7 cases (8.9%) showed tumor-specific phosphorylation of MAPK, whereas 41 cases (52%) showed more than 2-fold lower levels of MAPK phosphorylation in tumor tissues. In contrast to MAPK, 42 cases (53%) showed tumor-specific increase in STAT3 expression. In addition, 15 cases (19%) showed tumor-specific increase of STAT3 phosphorylation and 51 cases (65%) had STAT3 phosphorylation proportional to its expression. Moreover, exogenous expression of either JAB or dominant negative STAT3 in lung carcinoma cell lines led to the suppression of STAT3 phosphorylation and the drastic reduction of anchorage-independent growth of the cells. Taken together, our results suggest that JAK-STAT3 signaling has a pivotal role for oncogenic growth of lung carcinoma cells.
引用
收藏
页码:931 / 934
页数:4
相关论文
共 50 条
  • [21] Novel STAT3 inhibitors targeting the STAT3 dimerization
    Hua, Yaping
    Azeem, Waqas
    Oyan, Anne Margrete
    Kalland, Karl-Henning
    CANCER RESEARCH, 2022, 82 (12)
  • [22] Disruption of STAT3 by Niclosamide Reverses Radioresistance of Human Lung Cancer
    You, Shuo
    Li, Rui
    Park, Dongkyoo
    Xie, Maohua
    Sica, Gabriel L.
    Cao, Ya
    Xiao, Zhi-Qiang
    Deng, Xingming
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (03) : 606 - 616
  • [23] Expression analysis of Stat3 in human lung carcinoma
    王红
    韩一平
    Journal of Medical Colleges of PLA, 2002, (01) : 69 - 72
  • [24] Development of SH2 domain proteomimetics as potent disruptors of oncogenic Stat3:Stat3 dimerization
    Drewry, Joel A.
    Gunning, Patrick T.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [25] Infectious Clinical Phenotype of STAT3 Dominant-Negative Disease
    Ali, Sania
    Williamson, Hastings
    Urban, Amanda
    Lafeer, Christine
    Roy, Susan
    Ulrick, Jean
    Heimall, Jennifer
    Freeman, Alexandra
    JOURNAL OF CLINICAL IMMUNOLOGY, 2022, 42 (SUPPL 1) : S101 - S102
  • [26] BCL3 exerts an oncogenic function by regulating STAT3 in human cervical cancer
    Zhao, Hu
    Wang, Wuliang
    Zhao, Qinghe
    Hu, Guiming
    Deng, Kehong
    Liu, Yuling
    ONCOTARGETS AND THERAPY, 2016, 9 : 6619 - 6629
  • [27] Impact of Early Intervention for STAT3 Dominant-Negative Disease
    An, Zixiao
    Urban, Amanda
    Roy, Susan
    Ali, Sania
    Heimall, Jennifer
    Dimitriades, Victoria
    Williams, Kelli
    Freeman, Alexandra
    CLINICAL IMMUNOLOGY, 2023, 250 : 102 - 102
  • [28] STAT3 in arsenic lung carcinogenicity
    Chen, Gang
    ONCOIMMUNOLOGY, 2015, 4 (04):
  • [29] PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies
    Sen, Malabika
    Kindsfather, Audrey
    Danilova, Ludmila
    Zhang, Feng
    Colombo, Raffaele
    LaPorte, Matthew G.
    Kurland, Brenda F.
    Huryn, Donna M.
    Wipf, Peter
    Herman, James G.
    EPIGENETICS, 2020, 15 (6-7) : 604 - 617
  • [30] Eriocalyxin B Inhibits STAT3 Signaling by Covalently Targeting STAT3 and Blocking Phosphorylation and Activation of STAT3
    Yu, Xiaokui
    He, Li
    Cao, Peng
    Yu, Qiang
    PLOS ONE, 2015, 10 (05):